<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172925</url>
  </required_header>
  <id_info>
    <org_study_id>2009-TIDAL</org_study_id>
    <nct_id>NCT01172925</nct_id>
  </id_info>
  <brief_title>Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer</brief_title>
  <acronym>TIDAL</acronym>
  <official_title>Randomized Phase II Crossover Study of Tiotropium For Dyspnea in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The feeling of shortness of breath is very common in lung cancer. It is uncomfortable for
      patients and upsetting for their family. Although drugs like morphine and oxygen can help
      some patients feel better, they don't help everybody, and they are not used in patients with
      early symptoms. More relief is needed for these patients. The investigators are studying a
      drug called tiotropium, which is used in emphysema. It is an inhaler that opens the airways
      to allow easier breathing. Every patient will get the drug but also a placebo, in a random
      (flip of a coin) order. They will get each for 2 weeks. The investigators will see if they
      feel better with the drug.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 question Cancer Dyspnea Scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>10 point Dyspnea numeric scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 point Cough scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume 1 second (L/s) and Forced Vital Capacity (L)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>NSCLC</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Inhaler</description>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven incurable stage IIIb or stage IV non-small cell
             lung cancer.

          2. Dyspnea as defined by a score of 2 or higher on the 10-point Dyspnea Numeric Scale
             (Appendix 2).

          3. New dyspnea or worsening dyspnea within the last 6 months per patient reporting.

        Exclusion Criteria:

          1. Age &lt; 18.

          2. An FEV1 / FVC ratio &lt; 0.7 with an FEV1 of &lt; 80% predicted post-bronchodilator.

          3. Life expectancy &lt; 3 months.

          4. Significant worsening of dyspnea over the last week such that an acute cardiac or
             respiratory condition is considered likely (e.g. pneumonia, heart failure).

          5. Myocardial infarction within the previous month.

          6. Heart rate ≥ 120.

          7. Active tuberculosis or tuberculosis receiving antibiotic therapy.

          8. Current or previous use of ipratropium, tiotropium, or oxitropium (see Appendix 6).

          9. Sensitivity to atropine.

         10. Pre-existing diagnosis of asthma or moderate to severe Chronic Obstructive Pulmonary
             Disease

         11. Use of beta-adrenergic bronchodilators more than once per week.

         12. Use of experimental therapy with known cholinergic or adrenergic effects.

         13. Uncontrolled glaucoma.

         14. Urinary retention.

         15. An active upper or lower respiratory infection or having taken antibiotics for any
             recent respiratory infection within 4 weeks.

         16. Symptomatic pleural or pericardial effusion.

         17. Evidence of reversible proximal endobronchial obstruction.

         18. Oxygen saturation &lt; 90%.

         19. A hemoglobin of &lt; 100 g/litre. Testing is to be within 4 weeks of randomization.

         20. Calculated or urine creatinine clearance ≤ 50 mL/min (see Appendix 5 for calculation).
             Testing it to be within 4 weeks of randomization.

         21. Weight loss &gt; 10% of usual body weight within 6 months.

         22. Known pregnancy or lactating.

         23. Unable to independently fill out quality of life forms or give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Goffin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre and McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Goffin, MD</last_name>
    <phone>905-387-9495</phone>
    <phone_ext>64603</phone_ext>
    <email>goffinj@hhsc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry McFarlan, RN</last_name>
    <phone>905-387-9495</phone>
    <phone_ext>64407</phone_ext>
    <email>smcfarla@hhsc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry McFarlan, RN</last_name>
      <phone>905-387-9495</phone>
      <phone_ext>64407</phone_ext>
      <email>smcfarla@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>John Goffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.jcc.hhsc.ca/body.cfm?id=91</url>
    <description>Juravinski Cancer Centre, Actively Accruing Clinical Trials</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>John Goffin</investigator_full_name>
    <investigator_title>Associate Prof</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>dyspnea</keyword>
  <keyword>phase II</keyword>
  <keyword>crossover</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

